-
1
-
-
84872620069
-
Global epidemiology of psoriasis: a systematic review of incidence and prevalence
-
Parisi R, Symmons DP, Griffiths CE et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013; 133:377–85.
-
(2013)
J Invest Dermatol
, vol.133
, pp. 377-385
-
-
Parisi, R.1
Symmons, D.P.2
Griffiths, C.E.3
-
3
-
-
63149104648
-
Increased expression of IL-12p70 and IL-23 by multiple dendritic cell and macrophage subsets in plaque psoriasis
-
Yawalkar N, Tscharner GG, Hunger RE, Hassan AS. Increased expression of IL-12p70 and IL-23 by multiple dendritic cell and macrophage subsets in plaque psoriasis. J Dermatol Sci 2009; 54:99–105.
-
(2009)
J Dermatol Sci
, vol.54
, pp. 99-105
-
-
Yawalkar, N.1
Tscharner, G.G.2
Hunger, R.E.3
Hassan, A.S.4
-
4
-
-
84922410788
-
Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis
-
Mease PJ. Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis. Curr Opin Rheumatol 2015; 27:127–33.
-
(2015)
Curr Opin Rheumatol
, vol.27
, pp. 127-133
-
-
Mease, P.J.1
-
5
-
-
58749105841
-
IL-23 promotes maintenance but not commitment to the Th17 lineage
-
Stritesky GL, Yeh N, Kaplan MH. IL-23 promotes maintenance but not commitment to the Th17 lineage. J Immunol 2008; 181:5948–55.
-
(2008)
J Immunol
, vol.181
, pp. 5948-5955
-
-
Stritesky, G.L.1
Yeh, N.2
Kaplan, M.H.3
-
6
-
-
43449111187
-
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
-
Leonardi CL, Kimball AB, Papp KA et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371:1665–74.
-
(2008)
Lancet
, vol.371
, pp. 1665-1674
-
-
Leonardi, C.L.1
Kimball, A.B.2
Papp, K.A.3
-
7
-
-
43449139402
-
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
-
Papp KA, Langley RG, Lebwohl M et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371:1675–84.
-
(2008)
Lancet
, vol.371
, pp. 1675-1684
-
-
Papp, K.A.1
Langley, R.G.2
Lebwohl, M.3
-
8
-
-
85008701919
-
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial
-
Blauvelt A, Papp KA, Griffiths CE et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol 2017; 76:405–17.
-
(2017)
J Am Acad Dermatol
, vol.76
, pp. 405-417
-
-
Blauvelt, A.1
Papp, K.A.2
Griffiths, C.E.3
-
9
-
-
84938992082
-
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
-
Griffiths CE, Reich K, Lebwohl M et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet 2015; 386:541–51.
-
(2015)
Lancet
, vol.386
, pp. 541-551
-
-
Griffiths, C.E.1
Reich, K.2
Lebwohl, M.3
-
10
-
-
84904545875
-
Secukinumab in plaque psoriasis–results of two phase 3 trials
-
Langley RG, Elewski BE, Lebwohl M et al. Secukinumab in plaque psoriasis–results of two phase 3 trials. N Engl J Med 2014; 371:326–38.
-
(2014)
N Engl J Med
, vol.371
, pp. 326-338
-
-
Langley, R.G.1
Elewski, B.E.2
Lebwohl, M.3
-
11
-
-
84942876148
-
Phase 3 studies comparing brodalumab with ustekinumab in psoriasis
-
Lebwohl M, Strober B, Menter A et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med 2015; 373:1318–28.
-
(2015)
N Engl J Med
, vol.373
, pp. 1318-1328
-
-
Lebwohl, M.1
Strober, B.2
Menter, A.3
-
12
-
-
85008601511
-
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial
-
Reich K, Armstrong AW, Foley P et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol 2017; 76:418–31.
-
(2017)
J Am Acad Dermatol
, vol.76
, pp. 418-431
-
-
Reich, K.1
Armstrong, A.W.2
Foley, P.3
-
13
-
-
84977071601
-
Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis
-
Gordon KB, Blauvelt A, Papp KA et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med 2016; 375:345–56.
-
(2016)
N Engl J Med
, vol.375
, pp. 345-356
-
-
Gordon, K.B.1
Blauvelt, A.2
Papp, K.A.3
-
14
-
-
84994735189
-
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: results from the CLEAR study
-
e9
-
Blauvelt A, Reich K, Tsai TF et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: results from the CLEAR study. J Am Acad Dermatol 2017; 76:60–69.e9. https://doi.org/10.1016/j.jaad.2016.08.008
-
(2017)
J Am Acad Dermatol
, vol.76
, pp. 60-69
-
-
Blauvelt, A.1
Reich, K.2
Tsai, T.F.3
-
15
-
-
84936763292
-
A phase 2 trial of guselkumab versus adalimumab for plaque psoriasis
-
Gordon KB, Duffin KC, Bissonnette R et al. A phase 2 trial of guselkumab versus adalimumab for plaque psoriasis. N Engl J Med 2015; 373:136–44.
-
(2015)
N Engl J Med
, vol.373
, pp. 136-144
-
-
Gordon, K.B.1
Duffin, K.C.2
Bissonnette, R.3
-
16
-
-
0018099294
-
Severe psoriasis–oral therapy with a new retinoid
-
Fredriksson T, Pettersson U. Severe psoriasis–oral therapy with a new retinoid. Dermatologica 1978; 157:238–44.
-
(1978)
Dermatologica
, vol.157
, pp. 238-244
-
-
Fredriksson, T.1
Pettersson, U.2
-
17
-
-
84924340693
-
The 5-point Investigator's Global Assessment (IGA) Scale: a modified tool for evaluating plaque psoriasis severity in clinical trials
-
Langley RG, Feldman SR, Nyirady J et al. The 5-point Investigator's Global Assessment (IGA) Scale: a modified tool for evaluating plaque psoriasis severity in clinical trials. J Dermatolog Treat 2016; 26:23–31.
-
(2016)
J Dermatolog Treat
, vol.26
, pp. 23-31
-
-
Langley, R.G.1
Feldman, S.R.2
Nyirady, J.3
-
18
-
-
0028332995
-
Dermatology Life Quality Index (DLQI)–a simple practical measure for routine clinical use
-
Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)–a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19:210–16.
-
(1994)
Clin Exp Dermatol
, vol.19
, pp. 210-216
-
-
Finlay, A.Y.1
Khan, G.K.2
-
19
-
-
84949198562
-
Measurement properties of a patient-reported outcome measure assessing psoriasis severity: the psoriasis symptoms and signs diary
-
Mathias SD, Feldman SR, Crosby RD et al. Measurement properties of a patient-reported outcome measure assessing psoriasis severity: the psoriasis symptoms and signs diary. J Dermatolog Treat 2016; 27:322–7.
-
(2016)
J Dermatolog Treat
, vol.27
, pp. 322-327
-
-
Mathias, S.D.1
Feldman, S.R.2
Crosby, R.D.3
-
21
-
-
84883134297
-
Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial
-
McInnes IB, Kavanaugh A, Gottlieb AB et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 2013; 382:780–9.
-
(2013)
Lancet
, vol.382
, pp. 780-789
-
-
McInnes, I.B.1
Kavanaugh, A.2
Gottlieb, A.B.3
-
22
-
-
84958043348
-
Patient-relevant treatment goals in psoriasis
-
Blome C, Gosau R, Radtke MA et al. Patient-relevant treatment goals in psoriasis. Arch Dermatol Res 2016; 308:69–78.
-
(2016)
Arch Dermatol Res
, vol.308
, pp. 69-78
-
-
Blome, C.1
Gosau, R.2
Radtke, M.A.3
-
23
-
-
84971333765
-
Clinical meaningfulness of complete skin clearance in psoriasis
-
e7
-
Strober B, Papp KA, Lebwohl M et al. Clinical meaningfulness of complete skin clearance in psoriasis. J Am Acad Dermatol 2016; 75:77–82.e7.
-
(2016)
J Am Acad Dermatol
, vol.75
, pp. 77-82
-
-
Strober, B.1
Papp, K.A.2
Lebwohl, M.3
|